{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:04:07Z","timestamp":1784707447688,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In ultrahypofractionated prostate stereotactic body radiation therapy (SBRT), genitourinary toxicity is the primary concern. Urethra sparing is a\u00a0strategy to mitigate potential negative effects of higher single doses to the urethra and bladder neck. We report on the dosimetric robustness of urethra sparing using a\u00a0catheter-based real-time monitoring device to track both interfractional variability and intrafractional motion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In 12\u00a0patients undergoing prostate ultrahypofractionated radiotherapy (UHFX), intrafractional prostate motion was monitored using a\u00a0HypoCath catheter (Micropos Medical\u2122, Gothenburg, Sweden), enabling urethra contouring on the planning CT and cone-beam (CB)CT images used for image-guided radiation therapy (IGRT). Dose coverage of both the urethra and the prostate clinical target volume (CTV) was calculated and compared between the planning CT and matched CBCTs. In addition, prostate motion was simulated and the cumulative dose coverage of prostate and urethra was calculated as a\u00a0function of time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The deviation between the planned and delivered urethral dose strongly correlated with elapsed time. Variations in the urethral curvature between planning CT and CBCT had only a\u00a0minimal effect on the dose distribution. The combined effects of deviations in the urethral shape and prostate movement resulted in a\u00a0mean dose deviation of 76\u202fcGy for the urethral D1 of all fractions and patients. The patient who experienced the greatest prostate motion showed an increase in urethral D1 of 1.94\u202fGy (+5.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Urethra sparing is feasible and only marginally impaired by variations in urethral shape but is sensitive to longer treatment durations due to intrafractional movement. Direct visualization of the urethra is not essential for IGRT, but intrafractional motion control is recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02547-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:30:38Z","timestamp":1779438638000},"page":"882-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetric robustness of urethra sparing in ultrahypofractionated prostate SBRT using catheter-based motion tracking"],"prefix":"10.1007","volume":"202","author":[{"given":"J.","family":"Berchtold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Annon-Eberharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Messner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gaisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"R\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2835-3049","authenticated-orcid":false,"given":"F.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"10196","key":"2547_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark\u00a0A, Gunnlaugsson\u00a0A, Beckman\u00a0L, Thellenberg-Karlsson\u00a0C, Hoyer\u00a0M, Lagerlund\u00a0M, Kindblom\u00a0J, Ginman\u00a0C, Johansson\u00a0B, Bjornlinger\u00a0K, Seke\u00a0M, Agrup\u00a0M, Fransson\u00a0P, Tavelin\u00a0B, Norman\u00a0D, Zackrisson\u00a0B, Anderson\u00a0H, Kjellen\u00a0E, Franzen\u00a0L, Nilsson\u00a0P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5\u2011year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet (London, England) 394(10196):385\u2013395. https:\/\/doi.org\/10.1016\/s0140-6736(19)31131-6","journal-title":"Lancet (London, England)"},{"issue":"15","key":"2547_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As\u00a0N, Griffin\u00a0C, Tree\u00a0A, Patel\u00a0J, Ostler\u00a0P, van der Voet\u00a0H, Loblaw\u00a0A, Chu\u00a0W, Ford\u00a0D, Tolan\u00a0S, Jain\u00a0S, Camilleri\u00a0P, Kancherla\u00a0K, Frew\u00a0J, Chan\u00a0A, Naismith\u00a0O, Armstrong\u00a0J, Staffurth\u00a0J, Martin\u00a0A, Dayes\u00a0I, Wells\u00a0P, Price\u00a0D, Williamson\u00a0E, Pugh\u00a0J, Manning\u00a0G, Brown\u00a0S, Burnett\u00a0S, Hall\u00a0E (2024) Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N\u00a0Engl J Med 391(15):1413\u20131425. https:\/\/doi.org\/10.1056\/NEJMoa2403365","journal-title":"N Engl J Med"},{"issue":"2","key":"2547_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s1470-2045(20)30581-7","volume":"22","author":"P Fransson","year":"2021","unstructured":"Fransson\u00a0P, Nilsson\u00a0P, Gunnlaugsson\u00a0A, Beckman\u00a0L, Tavelin\u00a0B, Norman\u00a0D, Thellenberg-Karlsson\u00a0C, Hoyer\u00a0M, Lagerlund\u00a0M, Kindblom\u00a0J, Ginman\u00a0C, Johansson\u00a0B, Bj\u00f6rnlinger\u00a0K, Seke\u00a0M, Agrup\u00a0M, Zackrisson\u00a0B, Kjell\u00e9n\u00a0E, Franz\u00e9n\u00a0L, Widmark\u00a0A (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22(2):235\u2013245. https:\/\/doi.org\/10.1016\/s1470-2045(20)30581-7","journal-title":"Lancet Oncol"},{"issue":"11","key":"2547_CR4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/s1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand\u00a0DH, Tree\u00a0AC, Ostler\u00a0P, van der Voet\u00a0H, Loblaw\u00a0A, Chu\u00a0W, Ford\u00a0D, Tolan\u00a0S, Jain\u00a0S, Martin\u00a0A, Staffurth\u00a0J, Camilleri\u00a0P, Kancherla\u00a0K, Frew\u00a0J, Chan\u00a0A, Dayes\u00a0IS, Henderson\u00a0D, Brown\u00a0S, Cruickshank\u00a0C, Burnett\u00a0S, Duffton\u00a0A, Griffin\u00a0C, Hinder\u00a0V, Morrison\u00a0K, Naismith\u00a0O, Hall\u00a0E, van As\u00a0N (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20(11):1531\u20131543. https:\/\/doi.org\/10.1016\/s1470-2045(19)30569-8","journal-title":"Lancet Oncol"},{"key":"2547_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-27","volume":"13","author":"F Eckert","year":"2013","unstructured":"Eckert\u00a0F, Alloussi\u00a0S, Paulsen\u00a0F, Bamberg\u00a0M, Zips\u00a0D, Spillner\u00a0P, Gani\u00a0C, Kramer\u00a0U, Thorwarth\u00a0D, Schilling\u00a0D, Muller\u00a0AC (2013) Prospective evaluation of a\u00a0hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC cancer 13:27. https:\/\/doi.org\/10.1186\/1471-2407-13-27","journal-title":"BMC cancer"},{"issue":"5","key":"2547_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","volume":"97","author":"DA Hamstra","year":"2017","unstructured":"Hamstra\u00a0DA, Mariados\u00a0N, Sylvester\u00a0J, Shah\u00a0D, Karsh\u00a0L, Hudes\u00a0R, Beyer\u00a0D, Kurtzman\u00a0S, Bogart\u00a0J, Hsi\u00a0RA, Kos\u00a0M, Ellis\u00a0R, Logsdon\u00a0M, Zimberg\u00a0S, Forsythe\u00a0K, Zhang\u00a0H, Soffen\u00a0E, Francke\u00a0P, Mantz\u00a0C, Rossi\u00a0P, DeWeese\u00a0T, Daignault-Newton\u00a0S, Fischer-Valuck\u00a0BW, Chundury\u00a0A, Gay\u00a0H, Bosch\u00a0W, Michalski\u00a0J (2017) Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys 97(5):976\u2013985. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.12.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2547_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.07.027","author":"F Wolf","year":"2015","unstructured":"Wolf\u00a0F, Gaisberger\u00a0C, Ziegler\u00a0I, Krenn\u00a0E, Scherer\u00a0P, Hruby\u00a0S, Schatz\u00a0T, Forstner\u00a0R, Holzinger\u00a0J, Vaszi\u00a0A, Kametriser\u00a0G, Steininger\u00a0P, Deutschmann\u00a0H, Sedlmayer\u00a0F (2015) Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency. Radiother Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2015.07.027","journal-title":"Radiother Oncol"},{"issue":"2","key":"2547_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","volume":"115","author":"DH Brand","year":"2023","unstructured":"Brand\u00a0DH, Br\u00fcningk\u00a0SC, Wilkins\u00a0A, Naismith\u00a0O, Gao\u00a0A, Syndikus\u00a0I, Dearnaley\u00a0DP, van As\u00a0N, Hall\u00a0E, Gulliford\u00a0S, Tree\u00a0AC (2023) The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha\/Beta (\u03b1\/\u03b2) Ratios in the CHHiP Trial. Int J Radiat Oncol Biol Phys 115(2):327\u2013336. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2547_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197757","volume":"13","author":"W Schaake","year":"2018","unstructured":"Schaake\u00a0W, van der Schaaf\u00a0A, van Dijk\u00a0LV, van den Bergh\u00a0ACM, Langendijk\u00a0JA (2018) Development of a\u00a0prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients. PLoS One 13(7):e0197757. https:\/\/doi.org\/10.1371\/journal.pone.0197757","journal-title":"PLoS One"},{"issue":"1","key":"2547_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/mp.16878","volume":"51","author":"J Pham","year":"2024","unstructured":"Pham\u00a0J, Neilsen\u00a0BK, Liu\u00a0H, Cao\u00a0M, Yang\u00a0Y, Sheng\u00a0K, Ma\u00a0TM, Kishan\u00a0AU, Ruan\u00a0D (2024) Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis. Med Phys 51(1):612\u2013621. https:\/\/doi.org\/10.1002\/mp.16878","journal-title":"Med Phys"},{"issue":"11","key":"2547_CR11","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","volume":"41","author":"J Le Guevelou","year":"2023","unstructured":"Le Guevelou\u00a0J, Bosetti\u00a0DG, Castronovo\u00a0F, Angrisani\u00a0A, de Crevoisier\u00a0R, Zilli\u00a0T (2023) State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature. World journal of urology 41(11):3287\u20133299. https:\/\/doi.org\/10.1007\/s00345-023-04579-6","journal-title":"World journal of urology"},{"key":"2547_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100907","volume":"51","author":"JL Gu\u00e9velou","year":"2025","unstructured":"Gu\u00e9velou\u00a0JL, Sargos\u00a0P, Ost\u00a0P, Alongi\u00a0F, Arcangeli\u00a0S, Berlin\u00a0A, Blanchard\u00a0P, Bruynzeel\u00a0A, Chapet\u00a0O, Dal Pra\u00a0A, Dess\u00a0RT, Guckenberger\u00a0M, Loblaw\u00a0A, Kishan\u00a0AU, Jereczek-Fossa\u00a0B, Pasquier\u00a0D, Shelan\u00a0M, Siva\u00a0S, Tree\u00a0AC, Zamboglou\u00a0C, Supiot\u00a0S, Murthy\u00a0V, Zilli\u00a0T (2025) Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey. Clin Transl Radiat Oncol 51:100907. https:\/\/doi.org\/10.1016\/j.ctro.2024.100907","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"2547_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","volume":"197","author":"F Wolf","year":"2021","unstructured":"Wolf\u00a0F, Sedlmayer\u00a0F, Aebersold\u00a0D, Albrecht\u00a0C, B\u00f6hmer\u00a0D, Flentje\u00a0M, Ganswindt\u00a0U, Ghadjar\u00a0P, H\u00f6cht\u00a0S, H\u00f6lscher\u00a0T, M\u00fcller\u00a0AC, Niehoff\u00a0P, Pinkawa\u00a0M, Schmidt-Hegemann\u00a0NS, Zamboglou\u00a0C, Zips\u00a0D, Wiegel\u00a0T (2021) Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 197(2):89\u201396. https:\/\/doi.org\/10.1007\/s00066-020-01723-8","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"2547_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00066-023-02125-2","volume":"200","author":"J Berchtold","year":"2024","unstructured":"Berchtold\u00a0J, Winkler\u00a0C, Karner\u00a0J, Groher\u00a0M, Gaisberger\u00a0C, Sedlmayer\u00a0F, Wolf\u00a0F (2024) Noninvasive inter- and intrafractional motion control in ultrahypofractionated radiation therapy of prostate cancer using RayPilot HypoCath\u2122-a substitute for gold fiducial-based IGRT? Strahlenther Onkol 200(3):195\u2013201. https:\/\/doi.org\/10.1007\/s00066-023-02125-2","journal-title":"Strahlenther Onkol"},{"key":"2547_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.phro.2022.11.008","volume":"24","author":"TM Janssen","year":"2022","unstructured":"Janssen\u00a0TM, van der Heide\u00a0UA, Remeijer\u00a0P, Sonke\u00a0JJ, van der Bijl\u00a0E (2022) A margin recipe for the management of intra-fraction target motion in radiotherapy. Phys Imaging Radiat Oncol 24:159\u2013166. https:\/\/doi.org\/10.1016\/j.phro.2022.11.008","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"1","key":"2547_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.semradonc.2003.10.003","volume":"14","author":"M van Herk","year":"2004","unstructured":"van Herk\u00a0M (2004) Errors and margins in radiotherapy. Semin Radiat Oncol 14(1):52\u201364. https:\/\/doi.org\/10.1053\/j.semradonc.2003.10.003","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"2547_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0360-3016(00)00518-6","volume":"47","author":"M van Herk","year":"2000","unstructured":"van Herk\u00a0M, Remeijer\u00a0P, Rasch\u00a0C, Lebesque\u00a0JV (2000) The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 47(4):1121\u20131135","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2547_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/jco.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer\u00a0LGW, Groen\u00a0VH, Pos\u00a0FJ, Haustermans\u00a0K, Monninkhof\u00a0EM, Smeenk\u00a0RJ, Kunze-Busch\u00a0M, de Boer\u00a0JCJ, van der Voort van Zijp\u00a0J, van Vulpen\u00a0M, Draulans\u00a0C, van den Bergh\u00a0L, Isebaert\u00a0S, van der Heide\u00a0UA (2021) Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase\u00a0III Trial. J\u00a0Clin Oncol 39(7):787\u2013796. https:\/\/doi.org\/10.1200\/jco.20.02873","journal-title":"J Clin Oncol"},{"key":"2547_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225795","author":"C Zamboglou","year":"2021","unstructured":"Zamboglou\u00a0C, Spohn\u00a0SKB, Adebahr\u00a0S, Huber\u00a0M, Kirste\u00a0S, Sprave\u00a0T, Gratzke\u00a0C, Chen\u00a0RC, Carl\u00a0EG, Weber\u00a0WA, Mix\u00a0M, Benndorf\u00a0M, Wiegel\u00a0T, Baltas\u00a0D, Jenkner\u00a0C, Grosu\u00a0AL (2021) PSMA-PET\/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13225795","journal-title":"Cancers (Basel)"},{"key":"2547_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.652678","volume":"11","author":"SKB Spohn","year":"2021","unstructured":"Spohn\u00a0SKB, Sachpazidis\u00a0I, Wiehle\u00a0R, Thomann\u00a0B, Sigle\u00a0A, Bronsert\u00a0P, Ruf\u00a0J, Benndorf\u00a0M, Nicolay\u00a0NH, Sprave\u00a0T, Grosu\u00a0AL, Baltas\u00a0D, Zamboglou\u00a0C (2021) Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A\u00a0Planning Study Based on Histopathology Reference. Frontiers in oncology 11:652678. https:\/\/doi.org\/10.3389\/fonc.2021.652678","journal-title":"Frontiers in oncology"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02547-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02547-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02547-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:54:16Z","timestamp":1784706856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02547-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2547"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02547-8","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Berchtold, M.\u00a0Schichl, N.\u00a0Annon-Eberharter, I.M.\u00a0Messner, C.\u00a0Gaisberger, F.\u00a0R\u00f6der, and F.\u00a0Wolf declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}]}}